PLA2R1

Across TCGA pan-cancer cohorts, PLA2R1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PLA2R1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PLA2R1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PLA2R1 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where PLA2R1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLA2R1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−1.197	<.001	11	view →
HNSC	All	III,IV	−0.696	<.001	11	view →
LSCC	All	All	+0.259	<.001	4	view →
LUAD	All	All	−0.346	.028	2	view →
PDAC	Male	III,IV	−0.593	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PLA2R1–CCRCC

Open the CCRCC breakdown →